Display options
Cite
Chen RE, Smith BK, Errico JM, et al. Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity. Cell Host Microbe. 2021;29(11):1634-1648.e5doi: 10.1016/j.chom.2021.09.006.
Chen, R. E., Smith, B. K., Errico, J. M., Gordon, D. N., Winkler, E. S., VanBlargan, L. A., Desai, C., Handley, S. A., Dowd, K. A., Amaro-Carambot, E., Cardosa, M. J., Sariol, C. A., Kallas, E. G., Sékaly, R. P., Vasilakis, N., Fremont, D. H., Whitehead, S. S., Pierson, T. C., & Diamond, M. S. (2021). Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity. Cell host & microbe, 29(11), 1634-1648.e5. https://doi.org/10.1016/j.chom.2021.09.006
Chen, Rita E, et al. "Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity." Cell host & microbe vol. 29,11 (2021): 1634-1648.e5. doi: https://doi.org/10.1016/j.chom.2021.09.006
Chen RE, Smith BK, Errico JM, Gordon DN, Winkler ES, VanBlargan LA, Desai C, Handley SA, Dowd KA, Amaro-Carambot E, Cardosa MJ, Sariol CA, Kallas EG, Sékaly RP, Vasilakis N, Fremont DH, Whitehead SS, Pierson TC, Diamond MS. Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity. Cell Host Microbe. 2021 Nov 10;29(11):1634-1648.e5. doi: 10.1016/j.chom.2021.09.006. Epub 2021 Oct 04. PMID: 34610295; PMCID: PMC8595868.
Copy Download .nbib Format: NLM
Share it on

Cell Host Microbe. 2021 Nov 10;29(11):1634-1648.e5. doi: 10.1016/j.chom.2021.09.006. Epub 2021 Oct 04.

Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity.

Cell host & microbe

Rita E Chen, Brittany K Smith, John M Errico, David N Gordon, Emma S Winkler, Laura A VanBlargan, Chandni Desai, Scott A Handley, Kimberly A Dowd, Emerito Amaro-Carambot, M Jane Cardosa, Carlos A Sariol, Esper G Kallas, Rafick-Pierre Sékaly, Nikos Vasilakis, Daved H Fremont, Stephen S Whitehead, Theodore C Pierson, Michael S Diamond

Affiliations

  1. Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110-1010, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110-1010, USA.
  2. Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110-1010, USA.
  3. Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-9806, USA.
  4. Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110-1010, USA.
  5. Institute of Health and Community Medicine, Universiti Sarawak Malaysia (UNIMAS), Kota Samarahan, Sarawak 94300, Malaysia; Integrated Research Associates, San Rafael, CA 94903, USA.
  6. Unit of Comparative Medicine, Caribbean Primate Research Center, University of Puerto Rico-Medical Sciences Campus, San Juan, PR 00936-5067, USA.
  7. Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo 01246-903, Brazil.
  8. Department of Microbiology and Immunology, Department of Pathology, Emory University School of Medicine, Atlanta, GA 30322, USA.
  9. Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA; Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA; Sealy Center for Vector-Borne and Zoonotic Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA.
  10. Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110-1010, USA; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110-1010, USA; Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110-1010, USA; The Andrew M. Jane M. Bursky Center for Human Immunology & Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110-1010, USA.
  11. Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110-1010, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110-1010, USA; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110-1010, USA; The Andrew M. Jane M. Bursky Center for Human Immunology & Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110-1010, USA; Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, Saint Louis, MO 63110-1010, USA. Electronic address: [email protected].

PMID: 34610295 PMCID: PMC8595868 DOI: 10.1016/j.chom.2021.09.006

Abstract

Although divergent dengue viruses (DENVs) have been isolated in insects, nonhuman primates, and humans, their relationships to the four canonical serotypes (DENV 1-4) are poorly understood. One virus isolated from a dengue patient, DKE-121, falls between genotype and serotype levels of sequence divergence to DENV-4. To examine its antigenic relationship to DENV-4, we assessed serum neutralizing and protective activity. Whereas DENV-4-immune mouse sera neutralize DKE-121 infection, DKE-121-immune sera inhibit DENV-4 less efficiently. Passive transfer of DENV-4 or DKE-121-immune sera protects mice against homologous, but not heterologous, DENV-4 or DKE-121 challenge. Antigenic cartography suggests that DENV-4 and DKE-121 are related but antigenically distinct. However, DENV-4 vaccination confers protection against DKE-121 in nonhuman primates, and serum from humans immunized with a tetravalent vaccine neutralize DENV-4 and DKE-121 infection equivalently. As divergent DENV strains, such as DKE-121, may meet criteria for serotype distinction, monitoring their capacity to impact dengue disease and vaccine efficacy appears warranted.

Copyright © 2021 Elsevier Inc. All rights reserved.

Keywords: antibody; dengue; divergent; genotype; neutralization; pathogenesis; protection; serotype

Conflict of interest statement

Declaration of interests M.S.D. is a consultant for Inbios, Vir Biotechnology, and Carnival Corporation and is on the scientific advisory boards of Moderna and Immunome. The Diamond Laboratory has rec

References

  1. J Virol. 2013 Dec;87(24):13729-40 - PubMed
  2. Mol Syst Biol. 2011 Oct 11;7:539 - PubMed
  3. Emerg Infect Dis. 2008 Mar;14(3):502-4 - PubMed
  4. Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):227-232 - PubMed
  5. Am J Trop Med Hyg. 2001 Nov;65(5):405-13 - PubMed
  6. J Infect Dis. 1973 Jul;128(1):7-14 - PubMed
  7. PLoS Pathog. 2013;9(12):e1003761 - PubMed
  8. Bacteriol Rev. 1950 Sep;14(3):225-32 - PubMed
  9. Genome Announc. 2017 Jul 20;5(29): - PubMed
  10. Cell Rep. 2020 Oct 6;33(1):108226 - PubMed
  11. J Virol. 2017 Feb 14;91(5): - PubMed
  12. Immunol Rev. 2015 Nov;268(1):340-64 - PubMed
  13. Cell Host Microbe. 2019 Nov 13;26(5):601-605.e3 - PubMed
  14. PLoS Pathog. 2017 Feb 16;13(2):e1006178 - PubMed
  15. Virology. 2006 Mar 1;346(1):53-65 - PubMed
  16. J Infect Dis. 2005 Mar 1;191(5):710-8 - PubMed
  17. PLoS One. 2013;8(1):e54220 - PubMed
  18. PLoS Pathog. 2008 May 09;4(5):e1000060 - PubMed
  19. Science. 2013 Oct 25;342(6157):415 - PubMed
  20. JAKSTAT. 2014 Jan 1;3(1):e27715 - PubMed
  21. Trends Microbiol. 2014 Mar;22(3):138-46 - PubMed
  22. J Hyg (Lond). 1982 Dec;89(3):355-64 - PubMed
  23. J Infect Dis. 2016 Oct 1;214(7):986-93 - PubMed
  24. Parasit Vectors. 2017 Aug 31;10(1):406 - PubMed
  25. Viruses. 2011 Sep;3(9):1562-608 - PubMed
  26. PLoS Negl Trop Dis. 2011 Aug;5(8):e1251 - PubMed
  27. J Infect Dis. 2002 May 1;185(9):1213-21 - PubMed
  28. Antiviral Res. 2016 Apr;128:7-19 - PubMed
  29. Infect Genet Evol. 2018 Aug;62:279-295 - PubMed
  30. J Gen Virol. 1989 Jan;70 ( Pt 1):37-43 - PubMed
  31. PLoS Negl Trop Dis. 2018 Feb 9;12(2):e0006209 - PubMed
  32. Science. 2004 Jul 16;305(5682):371-6 - PubMed
  33. Vaccine. 2015 Dec 10;33(50):7051-60 - PubMed
  34. Emerg Infect Dis. 2016 Dec;22(12):2146-2148 - PubMed
  35. PLoS Negl Trop Dis. 2017 May 15;11(5):e0005554 - PubMed
  36. Nature. 2013 Apr 25;496(7446):504-7 - PubMed
  37. Front Immunol. 2014 Sep 24;5:452 - PubMed
  38. J Virol. 2010 Sep;84(18):9227-39 - PubMed
  39. Am J Trop Med Hyg. 1990 Feb;42(2):179-84 - PubMed
  40. Lancet Infect Dis. 2020 Jul;20(7):839-850 - PubMed
  41. NPJ Vaccines. 2017 Jul 10;2:19 - PubMed
  42. Virology. 2008 Oct 25;380(2):296-303 - PubMed
  43. Hum Vaccin. 2006 Jul-Aug;2(4):167-73 - PubMed
  44. Nat Immunol. 2015 Feb;16(2):170-177 - PubMed
  45. Infect Genet Evol. 2003 May;3(1):19-28 - PubMed
  46. Virology. 1997 Apr 14;230(2):244-51 - PubMed
  47. J Virol. 2006 Dec;80(24):12149-59 - PubMed
  48. Curr Opin Virol. 2020 Aug;43:50-58 - PubMed
  49. Science. 2010 May 7;328(5979):745-8 - PubMed
  50. J Infect Dis. 2000 Jan;181(1):2-9 - PubMed
  51. J Theor Biol. 2001 Sep 7;212(1):57-69 - PubMed
  52. Nat Methods. 2020 Mar;17(3):261-272 - PubMed
  53. PLoS Negl Trop Dis. 2012;6(8):e1760 - PubMed
  54. Curr Protoc Microbiol. 2013 Nov 05;31:15D.3.1-15D.3.18 - PubMed
  55. Front Immunol. 2014 Apr 10;5:151 - PubMed
  56. Antiviral Res. 2017 Aug;144:44-47 - PubMed
  57. Nat Rev Microbiol. 2011 Jun 13;9(7):532-41 - PubMed
  58. Cell Rep. 2018 Oct 30;25(5):1214-1224 - PubMed
  59. Mol Ther. 2017 Oct 4;25(10):2323-2331 - PubMed
  60. Elife. 2017 Sep 05;6: - PubMed
  61. Cell Host Microbe. 2018 May 9;23(5):672-685.e6 - PubMed
  62. PLoS Negl Trop Dis. 2010 Mar 02;4(3):e617 - PubMed
  63. Vaccines (Basel). 2020 Jan 22;8(1): - PubMed
  64. Adv Virus Res. 2003;60:421-67 - PubMed
  65. mBio. 2013 Nov 19;4(6):e00873-13 - PubMed
  66. Science. 2017 Nov 17;358(6365):929-932 - PubMed
  67. J Infect Dis. 2017 Feb 1;215(3):351-358 - PubMed
  68. J Virol. 2000 Apr;74(7):3227-34 - PubMed
  69. Virology. 2008 Nov 10;381(1):67-74 - PubMed
  70. J Virol. 2007 Dec;81(23):12766-74 - PubMed
  71. J Virol. 2014 Oct;88(20):11726-37 - PubMed
  72. J Virol. 2013 Aug;87(16):8826-42 - PubMed
  73. Methods Mol Biol. 2014;1138:75-97 - PubMed
  74. N Engl J Med. 2018 Jul 26;379(4):327-340 - PubMed
  75. Virology. 2016 Oct;497:33-40 - PubMed
  76. Biotechniques. 2000 Jun;28(6):1102, 1104 - PubMed
  77. J Virol. 2006 Feb;80(3):1290-301 - PubMed
  78. Lancet. 2020 May 2;395(10234):1434-1443 - PubMed
  79. PLoS Negl Trop Dis. 2009;3(4):e423 - PubMed
  80. PLoS Pathog. 2013 Mar;9(3):e1003265 - PubMed
  81. Nat Rev Immunol. 2015 Dec;15(12):745-59 - PubMed
  82. Sci Rep. 2016 Feb 29;6:22356 - PubMed
  83. J Virol. 2010 Oct;84(20):10630-43 - PubMed
  84. J Virol. 1999 Jan;73(1):783-6 - PubMed
  85. Nat Microbiol. 2019 Sep;4(9):1508-1515 - PubMed
  86. N Engl J Med. 2015 Sep 24;373(13):1195-206 - PubMed
  87. PLoS Negl Trop Dis. 2016 Feb 05;10(2):e0004398 - PubMed
  88. Yale J Biol Med. 1970 Apr;42(5):311-28 - PubMed
  89. Ann Trop Med Parasitol. 1957 Dec;51(4):392-408 - PubMed
  90. Virology. 1990 Feb;174(2):479-93 - PubMed
  91. Science. 2015 Sep 18;349(6254):1338-43 - PubMed
  92. Acta Crystallogr D Biol Crystallogr. 2009 May;65(Pt 5):510-2 - PubMed
  93. Vaccines (Basel). 2020 Feb 02;8(1): - PubMed
  94. Am J Trop Med Hyg. 1952 Jan;1(1):30-50 - PubMed
  95. Microbiol Mol Biol Rev. 2016 Oct 26;80(4):989-1010 - PubMed
  96. Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):E8378-E8387 - PubMed

Publication Types

Grant support